press release

Nov. 18, 2020, 8:01 a.m. EST

Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

Personalis, Inc. /zigman2/quotes/212754973/composite PSNL -4.57% , a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.

The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.

ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.

NeXT Liquid Biopsy , a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.

Following are details for the Personalis presentations.

Scientific Poster Presentation

Poster Number   Title & Presenter   Dates
40   Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach Presenter: Simo V. Zhang, PhD   NOV 18-19 | Online

Following are details of an industry-sponsored symposium which will be presented at the meeting.

Satellite Symposia

Title   Title & Presenter   Dates
Sponsored Symposia   NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics Presenters: Erin N. Newburn, PhD and Dan Norton, MBA   NOV 18-19 | On Demand

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis [®] ImmunoID NeXT Platform [®] is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/

SOURCE: Personalis, Inc.

Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678 Media Contact:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

COMTEX_374629644/2456/2020-11-18T08:00:42

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2020

/zigman2/quotes/212754973/composite
US : U.S.: Nasdaq
$ 18.57
-0.89 -4.57%
Volume: 841,269
May 12, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$815.38 million
Rev. per Employee
$334,672
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.